Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACONNASDAQ:ANPCNASDAQ:BIOC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$7.60+7.0%$13.36$6.20▼$3,499.51$4.42M1.1355,869 shs33,618 shsANPCFresh2 Group$4.37$4.92$2.60▼$11.99$4.24M1.5526,396 shs35,704 shsBIOCBiocept$0.97$0.32▼$27.00$1.14M0.69764,067 shs751,400 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion+7.04%+6.29%-8.76%-93.28%-99.70%ANPCFresh2 Group0.00%0.00%0.00%0.00%0.00%BIOCBiocept0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACONAclarion1.4665 of 5 stars3.32.00.00.02.00.00.6ANPCFresh2 GroupN/AN/AN/AN/AN/AN/AN/AN/ABIOCBioceptN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONAclarion 2.50Moderate Buy$11,758.50154,617.11% UpsideANPCFresh2 Group 0.00N/AN/AN/ABIOCBiocept 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONAclarion$45.72K96.74N/AN/A($125.39) per share-0.06ANPCFresh2 Group$1.75M2.42N/AN/A($1.41) per share-3.10BIOCBiocept$25.86M0.00N/AN/A$15.60 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONAclarion-$4.91MN/A0.00N/AN/A-12,845.05%-422.87%-201.15%5/21/2025 (Estimated)ANPCFresh2 Group-$14.77MN/A0.00∞N/AN/AN/AN/AN/ABIOCBiocept-$32.09M-$58.45N/AN/AN/AN/A-468.87%-118.41%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONAclarionN/AN/AN/AN/AN/AANPCFresh2 GroupN/AN/AN/AN/AN/ABIOCBioceptN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONAclarionN/A2.802.80ANPCFresh2 GroupN/A0.320.32BIOCBiocept2.881.811.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONAclarion7.52%ANPCFresh2 Group45.84%BIOCBioceptN/AInsider OwnershipCompanyInsider OwnershipACONAclarion0.77%ANPCFresh2 Group26.22%BIOCBiocept1.61%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONAclarion7582,000505,000Not OptionableANPCFresh2 Group86970,000715,000Not OptionableBIOCBiocept502.63 million2.58 millionNot OptionableACON, ANPC, and BIOC HeadlinesRecent News About These CompaniesCirculating Tumor Cells Prognostic Technologies Market Outlook, In-Depth Analysis of Trends, Innovations, and Growth Projections 2024-2032October 23, 2024 | taiwannews.com.twNorth America Cancer Biopsy Market Forecast (2024-2032) Innovations, Market Dynamics, and Growth PotentialOctober 15, 2024 | taiwannews.com.twGlobal Circulating Tumor Cells Market to Reach $19.0 Billion by 2032 | 8.06% CAGROctober 3, 2024 | taiwannews.com.twGlobal Liquid Biopsy Market Set for Unprecedented Growth, Projected to Reach USD 10,938.6 million by 2033October 3, 2024 | fmiblog.comLiquid Biopsy Market Projected to Reach USD 10,938.6 Million by 2033 at a 21.7% of CAGRJuly 19, 2024 | pharmiweb.comFoundation Gives $2M to Set Up Margaret Faye Wilson Endowment at Salk InstituteMay 24, 2024 | msn.comWicklow Foundation Gives $2 Million to Establish Margaret Faye Wilson Endowment at Salk InstituteMay 23, 2024 | msn.comLiquid Biopsy Market to Grow at 13.1% CAGR, Revolutionizing Cancer DiagnosticsMay 15, 2024 | pharmiweb.comLiquid Biopsy Market Worth $11.3 billion | MarketsandMarkets.May 8, 2024 | finanznachrichten.deAkron residents could see water and sewer rate increases over federally mandated projectsMay 2, 2024 | msn.comBrain Cancer Diagnostics Market Outlook, Share, Key Players, Revenue, Size, and Forecast to 2024 to 2032April 17, 2024 | taiwannews.com.twPlus Therapeutics Inc.: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 6, 2024 | finanznachrichten.deCircular Genomics brings on 2 leadership hires following $8.3M raiseFebruary 27, 2024 | bizjournals.comCircular Genomics Strengthens Leadership Team with Key Commercial and Research HiresFebruary 26, 2024 | finance.yahoo.comInsights Into Challenges And Opportunities Of Liquid Biopsy IVD MarketFebruary 19, 2024 | opprairie.comBiocept (NASDAQ: BIOC)December 29, 2023 | fool.comSABCS Studies Shed Light on Targetable Mutations, Enhertu Efficacy in Leptomeningeal DiseaseDecember 10, 2023 | precisionmedicineonline.comPlus Therapeutics files to sell ordinary shares, warrantsNovember 22, 2023 | msn.comLiquid Biopsy Market Set for Explosive Growth, Expected to Hit US$ 101.86 Million with 16.6% CAGRNovember 21, 2023 | medgadget.comBiocept, Inc. (BIOCQ) Stock Historical Prices & Data - Yahoo FinanceNovember 10, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACON, ANPC, and BIOC Company DescriptionsAclarion NASDAQ:ACON$7.60 +0.50 (+7.04%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$7.58 -0.01 (-0.20%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.Fresh2 Group NASDAQ:ANPCAnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.Biocept NASDAQ:BIOCBiocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
